Stockreport

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

MiNK Therapeutics, Inc.  (INKT) 
PDF New clinical data show durable remissions and long-tail survivors including 2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launc [Read more]